FDA testing found toxic yellow oleander in Slim Elixir, DMagic Plus, and B. Magi, while two products also contained undeclared ingredients that create additional toxicologic hazards.

The U.S. Food and Drug Administration expanded its toxic yellow oleander safety alert on August 12, 2026, adding Slim Elixir, DMagic Plus, and B. Magi after agency testing found yellow oleander in all three products. The products were marketed for weight loss, and FDA is advising consumers to avoid them because yellow oleander exposure can cause neurologic, gastrointestinal, and cardiovascular effects that may be severe or fatal. [1]

For medical toxicology, the central issue is more specific than a generic contaminated-supplement warning. Yellow oleander contains cardiac glycosides capable of producing a digoxin-like poisoning syndrome, creating the possibility of clinically significant bradyarrhythmias, conduction abnormalities, ventricular dysrhythmias, hypotension, gastrointestinal symptoms, and other manifestations of cardiac-glycoside toxicity.

FDA also identified additional undeclared substances in two of the three newly added products. Laboratory analysis of DMagic Plus confirmed diclofenac, neriifolin, and thevetin B that were not listed on the product label. [2]

Separate FDA testing of B. Magi confirmed undeclared phenolphthalein, neriifolin, and thevetin B. [3]

The August 12 update does not, however, establish that adverse-event incidence has newly increased among users of these three products. FDA's current notice reports laboratory-confirmed product findings and an ongoing investigation; it does not provide a new product-specific incidence rate, a new case series, or evidence of a rising adverse-event rate for Slim Elixir, DMagic Plus, or B. Magi. [1]

What Happened?

FDA states that it added the three products to its yellow-oleander safety alert on August 12, 2026 after laboratory testing found toxic yellow oleander.

The agency's tested-product table identifies all three as 30-capsule products associated with Suerte Y Salud LLC and purchased from lamilagrosalab.com. For each of the three products, FDA's current recall-status field states that the selling firm has not responded to agency calls or emails. [1]

FDA's Health Fraud Product Database independently records DMagic Plus and B. MAGI on August 12, listing the same undeclared ingredients and identifying the regulatory action as a public notification. [4]

This distinction is important. FDA has analytically confirmed the hazardous ingredients, but the current table should not be described as a completed voluntary recall of these three products when FDA does not report one.

Why Yellow Oleander Is the Main Toxicology Concern

Yellow oleander is a poisonous plant containing cardenolide cardiac glycosides. The toxicologic concern is closely related to digitalis poisoning because these compounds interfere with cardiac cellular physiology in a way that can produce a digoxin-like clinical picture.

A CDC investigation of mislabeled weight-loss supplements previously found that yellow oleander contains thevetin B, a cardenolide with clinical effects similar to digoxin. [5]

That finding is directly relevant to the new FDA alert. Thevetin B and neriifolin identified in the newly tested products are not simply inert botanical contaminants; they are cardiac glycosides associated with potentially serious toxicity.

For clinicians who want additional context on conventional digitalis toxicity, MedicalToxic's Chronic Digoxin Toxicity Triggered by Acute Kidney Injury: A Case of Confusion and Bradycardia illustrates the neurologic and cardiovascular manifestations that can accompany clinically significant digoxin toxicity.

Yellow-oleander exposure is not identical to prescription digoxin overdose, but the shared cardiac-glycoside physiology helps explain why a product sold for weight loss can unexpectedly produce a dangerous cardiovascular toxidrome.

What Digoxin-Like Yellow-Oleander Poisoning Can Look Like

Historical clinical evidence helps define the risk.

In a CDC-described case involving a different mislabeled weight-loss product, a 23-month-old child developed nausea, vomiting, bradycardia, and hypotension after exposure. ECG findings included sinus bradycardia, frequent premature ventricular complexes, and ST-segment changes consistent with cardenolide toxicity. [5]

That case did not involve Slim Elixir, DMagic Plus, or B. Magi and should not be interpreted as an adverse event attributed to the products newly added in August 2026. It is relevant because it demonstrates the type of clinical toxicity that yellow-oleander cardiac glycosides can produce.

Clinically important features of cardiac-glycoside poisoning may therefore include gastrointestinal illness accompanied by bradycardia, conduction disturbances, ventricular ectopy or other dysrhythmias, hypotension, and electrolyte abnormalities.

A history focused only on prescription medications may miss the exposure entirely. Weight-loss preparations, botanical products, herbal capsules, and other products marketed as “natural” should be specifically considered when the clinical picture suggests cardiac-glycoside toxicity.

A Serum Digoxin Level Can Be Misleading

Yellow-oleander poisoning also creates an important diagnostic trap.

CDC reports that nondigoxin cardiac glycosides can cross-react with some serum digoxin immunoassays. A patient with yellow-oleander toxicity may therefore have a detectable digoxin result even without having taken pharmaceutical digoxin. [5]

However, the reported digoxin concentration does not accurately quantify the amount of thevetin B or other nondigoxin cardiac glycosides in the blood. CDC specifically cautions that serum digoxin assays are not reliable for detecting thevetin B and other cardiac glycosides besides digoxin. [5]

Clinicians should therefore interpret a positive or measurable digoxin result as a potentially useful clue in the appropriate exposure context rather than treating the numerical value as a direct measurement of yellow-oleander toxin burden.

Clinical presentation, ECG findings, electrolyte abnormalities, hemodynamic status, exposure history, and consultation with a poison center or medical toxicologist remain central to assessment.

MedicalToxic provides additional context on specialist poison-management workflows in The Role of Poison Center Calls: Managing Poisoning Cases from Emergency Calls to Critical Decisions.

DMagic Plus Adds a Hidden Diclofenac Exposure

DMagic Plus presents a second toxicologic problem beyond its yellow-oleander content.

FDA laboratory analysis confirmed diclofenac, neriifolin, and thevetin B, none of which appeared on the product label. [2]

Diclofenac is a nonsteroidal anti-inflammatory drug. FDA warns that NSAIDs can increase the risk of serious cardiovascular events such as heart attack and stroke and can cause severe gastrointestinal complications including bleeding, ulceration, and potentially life-threatening perforation. FDA also notes that diclofenac can interact with other medications, particularly other NSAID-containing products. [2]

For a consumer who does not know diclofenac is present, medication reconciliation may therefore fail to identify a clinically relevant NSAID exposure.

The important distinction is that diclofenac represents an additional hidden pharmaceutical hazard, while the neriifolin and thevetin B findings reinforce the central cardiac-glycoside poisoning risk.

B. Magi Contains Undeclared Phenolphthalein

FDA identified a different undeclared chemical in B. Magi.

Laboratory testing confirmed phenolphthalein, neriifolin, and thevetin B that were not declared on the product label. FDA states that phenolphthalein is not an active ingredient in any approved U.S. drug and that studies suggest it may increase cancer risk. [3]

The immediate toxicologic concern from yellow oleander remains distinct from the potential risk associated with phenolphthalein. Combining the findings into a single generic claim of “contamination” would obscure the fact that different undeclared substances create different types of risk.

MedicalToxic has covered a comparable labeling problem in another product class in Psilocybin Gummies Contaminated with Dangerous Synthetic Compounds, where analytical testing showed that marketed product identity did not reliably predict the substances consumers were actually exposed to.

Laboratory Confirmation Is Not the Same as an Adverse-Event Signal

The evidence behind the August 12 alert should be described precisely.

What FDA has confirmed

FDA has confirmed through laboratory testing that:

• Slim Elixir contains toxic yellow oleander.

• DMagic Plus contains toxic yellow oleander and undeclared diclofenac, neriifolin, and thevetin B.

• B. Magi contains toxic yellow oleander and undeclared phenolphthalein, neriifolin, and thevetin B.

• Yellow oleander can cause neurologic, gastrointestinal, and cardiovascular adverse effects that may be severe or fatal.

• FDA continues to test botanical products marketed for weight loss for toxic yellow oleander. [1] [2] [3]

What FDA has not established in this update

The August 12 update does not report:

• a new number of poisoning cases specifically linked to these three products;

• an incidence or attack rate among people who used them;

• a newly demonstrated increase in adverse-event incidence;

• a new clinical case series involving Slim Elixir, DMagic Plus, or B. Magi; or

• evidence that every person who used one of the products developed toxicity. [1]

Earlier FDA updates to the broader yellow-oleander investigation have discussed adverse-event reports involving other products. Those historical reports should not be reassigned to the three products newly added on August 12.

FDA states that its broader investigation remains ongoing and that it continues monitoring the market for adverse events, product complaints, and other emerging issues. [1]

What Consumers Should Do

FDA advises consumers to stop using and dispose of products included in the yellow-oleander alert. [1]

The agency also advises people who have taken one of the products to contact a healthcare professional immediately, even if they have not used the product recently, so an appropriate evaluation can be performed.

FDA recommends calling 911 or obtaining emergency medical assistance for serious side effects and directs consumers to poison-control resources for exposure guidance. [1]

Healthcare professionals and consumers can also report adverse events associated with DMagic Plus or B. Magi through FDA's MedWatch program. [2] [3]

Practical Implications for Clinicians

For emergency clinicians, medical toxicologists, pharmacists, and poison-center specialists, the new FDA findings broaden the list of weight-loss products capable of producing an unexpected cardiac-glycoside exposure.

When otherwise unexplained nausea or vomiting occurs with bradycardia, conduction abnormalities, ventricular ectopy, hypotension, or other findings compatible with cardiac-glycoside poisoning, the exposure history should specifically include weight-loss products and botanical supplements.

The product label cannot be assumed to identify the full exposure.

DMagic Plus demonstrates this clearly: the user may be exposed simultaneously to plant-derived cardiac glycosides and an undisclosed NSAID. B. Magi similarly combines yellow-oleander glycosides with undeclared phenolphthalein. [2] [3]

A measurable digoxin result should also be interpreted cautiously when plant cardiac-glycoside exposure is suspected because immunoassay cross-reactivity does not provide an accurate quantitative measurement of the nondigoxin glycoside concentration. [5]

In clinically significant suspected cardiac-glycoside poisoning, management decisions should be based on the patient's overall clinical condition and specialist toxicology guidance rather than on a serum digoxin number alone.

What Is Genuinely New?

The key new development is straightforward: on August 12, 2026, FDA added exactly three products—Slim Elixir, DMagic Plus, and B. Magi—to its toxic yellow-oleander safety alert after laboratory testing found yellow oleander in all three. [1]

The DMagic Plus and B. Magi notifications add another layer of information because FDA identified additional undeclared ingredients in both products. [2] [3]

FDA also says that its surveillance has expanded beyond products labeled as tejocote root or Brazil seed to other botanical products marketed for weight loss, and the agency intends to continue testing and add products that test positive for toxic yellow oleander. [1]

This means the August 12 additions are best understood as part of an ongoing analytical surveillance investigation—not as the endpoint of the FDA's yellow-oleander investigation.

Limitations and Remaining Unknowns

Several clinically relevant questions remain unanswered in the public FDA materials.

FDA does not provide the concentration of yellow-oleander cardiac glycosides in each capsule or a quantitative dose of neriifolin or thevetin B. The public notifications likewise do not provide quantitative concentrations for diclofenac or phenolphthalein.

FDA also does not provide the number of consumers who used these three products, the prevalence of exposure, or a product-specific rate of illness.

The available evidence therefore establishes the presence of hazardous undeclared substances and their known toxicologic significance, but it cannot establish how frequently users of Slim Elixir, DMagic Plus, or B. Magi have developed clinical toxicity.

These distinctions are particularly important when communicating risk: laboratory-confirmed adulteration justifies the FDA warning, but it should not be converted into an unsupported claim of a newly rising poisoning incidence.

Conclusion

FDA's August 12 expansion of its yellow-oleander alert identifies an important and potentially severe hidden exposure in products marketed for weight loss.

Slim Elixir, DMagic Plus, and B. Magi all tested positive for toxic yellow oleander. DMagic Plus also contained undeclared diclofenac, neriifolin, and thevetin B, while B. Magi contained undeclared phenolphthalein, neriifolin, and thevetin B. [1] [2] [3]

For clinicians and consumers, the central toxicology message is not simply that these are “contaminated supplements.” The more clinically meaningful concern is unexpected exposure to plant cardiac glycosides capable of causing digoxin-like poisoning, sometimes alongside additional undeclared pharmacologically active substances.

At the same time, the evidence should not be overstated. FDA has analytically confirmed the adulteration, but the August 12 update does not demonstrate a newly increased incidence of adverse events from these three products.

References

1. U.S. Food and Drug Administration. (2026, August 12). FDA Issues Warning About Certain Products Containing Toxic Yellow Oleander.

2. U.S. Food and Drug Administration. (2026, August 12). DMagic Plus may be harmful due to hidden ingredients.

3. U.S. Food and Drug Administration. (2026, August 12). B. MAGI may be harmful due to hidden ingredients.

4. U.S. Food and Drug Administration. (2026). Health Fraud Product Database.

5. Berland, N., Kababick, J., Santos, C., & Calello, D. P. (2023). Notes from the Field: Online Weight Loss Supplements Labeled as Tejocote (Crataegus mexicana) Root, Substituted with Yellow Oleander (Cascabela thevetia) — United States, 2022. Morbidity and Mortality Weekly Report, 72(37), 1016–1017. https://doi.org/10.15585/mmwr.mm7237a3